The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 includes several amendments to the Federal Food Drug and Cosmetic Act. One of those amendments eliminates the 30-month stay of approval of generic drugs when an Abbreviated New Drug Application is amended to include a paragraph IV certification for a patent that is listed with FDA after FDA accepts the Abbreviated New Drug Application.

Donald E. Segal contributed to this advisory.